Increased dose primary thromboprophylaxis in ambulatory patients with advanced pancreatic ductal adenocarcinoma, a single centre cohort study

BACKGROUND: Advanced pancreatic ductal adenocarcinoma (aPDAC) patients have a lifetime all type thromboembolic event (ATTE) rate of 25–35%. Efficacy and safety of increased dose primary thromboprophylaxis (IDPTP) with low molecular heparin (LMWH) given for 3 months has been shown in two prospective...

Descripción completa

Detalles Bibliográficos
Autores principales: Maraveyas, Anthony, Haque, Farzana, Muazzam, Iqtedar Ahmed, Ilyas, Waqas, Bozas, George
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7257220/
https://www.ncbi.nlm.nih.gov/pubmed/32514256
http://dx.doi.org/10.1186/s12959-020-00222-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7257220/
https://www.ncbi.nlm.nih.gov/pubmed/32514256
http://dx.doi.org/10.1186/s12959-020-00222-1

Ejemplares similares